Fundz

Altimmune

Morristown, New Jersey, United States · Biopharma, Biotechnology, Health Care

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obe

Key facts

Headquarters
Morristown, New Jersey, United States
Employees
59
Industries
Biopharma, Biotechnology, Health Care
Status
Public (ALT)
Website
altimmune.com
LinkedIn
Company page

Recent activity at Altimmune

  • : Altimmune Appoints Richard Menziuso as Vice President, Global Controller
  • : SEC 8-K (5.02):
  • : SEC 8-K (5.02): On September 24, 2026, Altimmune, Inc. appointed Richard Menziuso as the Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Mr. Menziuso brings 28 years of finance and accounting experience, notably serving as Vice President, Corporate Controller at Centessa Pharmaceuticals until its recent acquisition by Eli Lilly. His appointment is expected to enhance the financial leadership of Altimmune as they continue to advance in the biopharmaceutical sector. Gregory Weaver will maintain his position as the Chief Financial Officer, ensuring continuity in the company's financial strategy during this transition.
  • : SEC 8-K (8.01): On July 28, 2026, Altimmune, Inc. announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide, demonstrating significant efficacy in reducing heavy drinking days in patients with moderate to severe Alcohol Use Disorder (AUD). The trial achieved its primary endpoint with notable statistical significance, indicating that the treatment had a beneficial impact compared to a placebo. Key secondary endpoints were also met, during which participants showed improvements in the World Health Organization Risk Drinking Level and in phosphatidyl ethanol levels. The company plans to request an End-of-Phase 2 meeting with the FDA based on these promising outcomes, which could potentially lead to further development and approval processes. This strategic communication highlights a positive trajectory for the investigational drug and its possible future in market treatment options for AUD.
  • : SEC 8-K (8.01): On June 16, 2026, Altimmune, Inc. announced its plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later in the year. This strategic move is aimed at positioning the company within a strong biopharmaceutical hub to attract top-tier talent and support its growth as a late-stage development firm. Altimmune has signed a 5-year office lease agreement for the new headquarters, with annual rent payments projected at approximately $300,000. This relocation is anticipated to yield long-term cost efficiencies for the company as it works towards advancing its business objectives.
  • : SEC 8-K (8.01): On June 16, 2026, Altimmune, Inc. announced plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey later this year. The new headquarters is strategically located in an area with a strong presence of biopharmaceutical companies, which is anticipated to enhance the Company’s ability to attract top-tier talent. The Company has entered into a 5-year office lease agreement, committing to annual rent payments of approximately $300,000. This move is expected to help Altimmune achieve cost efficiencies and support its growth as a late-stage development company.
  • : SEC 8-K (1.01): On April 22, 2026, Altimmune, Inc. entered into an underwriting agreement with Leerink Partners LLC and Barclays Capital Inc., wherein the Company agreed to issue and sell a total of 64,250,000 shares of its common stock at a public offering price of $3.00 per share, alongside warrants to purchase common stock. Additionally, the Company offered 10,750,000 pre-funded warrants for $2.999 each as an alternative for certain investors. The offering closed on April 24, 2026, and it is expected to yield approximately $211.2 million in net proceeds after deducting related expenses. These funds are intended to advance the clinical development of pemvidutide and support the preparation for a global pivotal Phase 3 trial in metabolic dysfunction-associated steatohepatitis.
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On January 27, 2026, Altimmune, Inc. entered into a Securities Purchase Agreement with a fundamental institutional investor, issuing 12,397,920 shares of Common Stock and pre-funded warrants to purchase up to 4,647,534 shares of Common Stock. The Offering is expected to close on or about January 29, 2026, with gross proceeds estimated at $75 million. The company also entered into a Placement Agency Agreement with Titan Partners, with customary terms and a 30-day lock-up agreement for company directors and executives. This transaction is made under the effective shelf registration statement filed with the SEC on December 5, 2025.
  • : SEC 8-K (8.01): On December 19, 2025, the Company announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, which is a glucagon/GLP-1 dual receptor agonist aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This trial demonstrated significant improvements in key non-invasive tests measuring liver fibrosis and inflammation over 48 weeks. The results showed that pemvidutide, at doses of 1.2 mg and 1.8 mg, achieved notable reductions in markers such as ELF and LSM compared to placebo. The trial enrolled 212 participants with biopsy-confirmed MASH, suggesting a positive progression in the treatment's efficacy and a good tolerability profile, which is crucial for its potential market impact.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Leadership

  • Richard Menziuso, Vice President
  • Laura Gibbs, Chief Operating Officer
  • M. Scott Harris, Chief Executive Officer
  • Lisa Simpson-Smith, Hr Professional
  • Andrew Shutterly, Experienced and Effective Accountant
  • Aklilu Meshesha, Director of Financial Reporting
  • Kent Tapper, Recently Retired
  • Vyjayanthi Krishnan, Technical Lead On Pd Studies
  • Bertrand Georges, Chief Technology Officer
  • Sarah Browne, Not Specified In the Text
  • Audrey Sykes, Experience In Life Science and Diagnostics
  • Siavoche Siassi, Life Sciences Strategy and Marketing Professional

Verified email and direct lines for Altimmune’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Altimmune in the news

Companies similar to Altimmune

About Altimmune: questions and answers

What does Altimmune do?

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obe

Where is Altimmune headquartered?

Altimmune is headquartered in Morristown, New Jersey, United States.

How many employees does Altimmune have?

Altimmune has about 59 employees.

Who leads Altimmune?

Richard Menziuso is a Vice President at Altimmune.

What is the latest news on Altimmune?

On Sep 29, 2026, Altimmune Appoints Richard Menziuso as Vice President, Global Controller

Is Altimmune a public company?

Yes. Altimmune is publicly traded under the ticker ALT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Altimmune across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.